Clinical Trial

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
Trial Details
NCT Number NCT06521255
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions DLBCL
Enrollment 244 participants
Start Date 2024-05-07
Primary Completion 2028-09 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2024-07-25